Holistic Approach to the Industry 4.0 Investment Breaking Down the Fences Between R&D & Manufacturing
14th March 2022 | 10:00am EST / 2:00pm GMT / 3:00pm CET | Christos Varsakelis, Team Lead Artificial Intelligence/Machine Learning at The Janssen Pharmaceutical Companies of Johnson & Johnson and Shilpa Nargund, Director at Insilico Biotechnology Pte. Ltd., Singapore |WATCH FOR FREE
Bioprocessing 4.0 is a novel terminology that is typically identified as Industry 4.0 avatar in Bioprocessing. The overall concept of Bioprocessing 4.0 has been increasingly gaining traction and this trend is robustly projected to remain strong. Interestingly, even in business fora, the majority of discussions on Bioprocessing 4.0 are predominately technical. Emphasis is placed on the exposition of existing capabilities, and those under development, a situation reminiscent of marketing campaigns. Even when brought up, business arguments remain largely qualitative which, in turn, constitutes a conundrum given that Bioprocessing 4.0 is de facto an investment agenda. In this talk, we deviate from the technical land and re-examine Bioprocessing 4.0 through the lenses of an informed investor. We show that optimizing Return on Investment requires the adoption of a holistic approach to Bioprocessing 4.0; an approach that simultaneously considers R&D and manufacturing. However, the usual fences between R&D and manufacturing, a manifestation of siloing that plagues big corporations, can jeopardize the overall business case. The main corollary of our analysis is that success predicates strongly on treating R&D and manufacturing as a continuum.
Presented by Christos Varsakelis, Team Lead Artificial Intelligence/Machine Learning at The Janssen Pharmaceutical Companies of Johnson & Johnson
Christos Varsakelis leads the AI/ML team for Drug Discovery in the Janssen Pharmaceutical Companies aiming at the acceleration of development timelines and increase of probability of technical success. Prior joining Janssen, Christos was a Senior Manager of Global Analytics & Innovation in GSK Vaccines focusing on in silico Bioprocess development. Besides working in the pharmaceutical industry, Christos has an accumulated professional experience that spans across Geoconsulting, the stock market and the chemical industry. Christos is in hold of a Ph.D. in fluid mechanics in UCLouvain in Belgium. He is also in hold of a B.A. in Mathematics from the Aristotle University of Thessaloniki, Greece and an M.Sc. in Applied Mathematics from the ETH Zurich, Switzerland. His moto is innovation = cash.
Followed by Shilpa Nargund, Director at Insilico Biotechnology Pte. Ltd., Singapore
Shilpa Nargund is the Managing Director at Yokogawa Insilico Biotechnology Pte. Ltd., Singapore. She leads Insilico’s business development in the APAC region. Previously, she spent 5 years in early and late-stage cell culture process development teams in Biopharma companies across USA, India and Singapore. She is a Chemical Engineer with a Bachelor’s from Institute of Chemical Technology, Mumbai, India and a PhD from the University of Maryland, College Park, USA
Sponsored by Yokogawa Insilico Biotechnology GmbH
Yokogawa Insilico Biotechnology GmbH develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Ground breaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Yokogawa Insilico Biotechnology GmbH, based in Stuttgart, Germany, is a subsidiary of Yokogawa Corporate Electric Corporation, based in Tokyo, Japan.